Syngene International receives EIR from USFDA for Biocon Park facility, inspection concludes with VAI classification
Syngene International Limited has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its GMP manufacturing facilities located at Biocon Park, SEZ, Bengaluru. This follows the routine current Good Manufacturing Practices (cGMP) inspection conducted between February 10 and February 20, 2025.
As per the EIR dated June 11, 2025, the inspection has been classified as Voluntary Action Indicated (VAI). The USFDA has reviewed and accepted Syngene's responses along with the Corrective and Preventive Action (CAPA) plans submitted in response to the inspectional observations.
Advertisement
The company will continue to provide periodic updates to the USFDA on the implementation status of the corrective actions. Syngene reiterates its commitment to maintaining the highest standards of regulatory compliance.
This inspection outcome is not expected to have any adverse impact on the Company's financial performance or operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
a day ago
- Business Upturn
Sun Pharma's Halol facility receives form 483 with 8 observations from US FDA
By Aman Shukla Published on June 14, 2025, 09:42 IST Sun Pharmaceutical Industries Limited, one of India's leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) at its Halol manufacturing facility located in Gujarat, India. The inspection was conducted from June 2 to June 13, 2025, as part of the regulatory authority's routine evaluation of current Good Manufacturing Practices (GMP) compliance. At the end of the inspection, the US FDA issued a Form 483 to the company, outlining eight observations. In a regulatory filing, Sun Pharma stated: 'We hereby inform that the US FDA conducted a GMP inspection of our Halol facility from 02 June to 13 June 2025. At the conclusion of the inspection, the US FDA issued a Form-483 with 8 observations.' A Form 483 is issued by the US FDA when its investigators observe any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related regulations. These observations are based on conditions found during routine inspections and are intended to prompt the company to take corrective actions. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
a day ago
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
AbbVie Secures FDA Approval to Expand Mavyret's Label
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a . The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), for treating Hepatitis C. The updated approval allows Mavyret—made from the antiviral agents glecaprevir and pibrentasvir—to be used in the US for both adults and children aged three and older with acute or chronic Hepatitis C, provided they do not have cirrhosis or have compensated cirrhosis. Eligible patients can complete treatment in eight weeks. This decision is based on results from a Phase 3 study, which showed the therapy to be safe and effective for acute cases. Mavyret was initially approved in 2017 for newly diagnosed adult Hepatitis C patients. AbbVie Inc. (NYSE:ABBV) is an international biopharmaceutical firm dedicated to creating and providing advanced treatments for challenging health conditions. The company concentrates on key areas such as immunology, cancer, neuroscience, eye care, and aesthetics. Its goal is to improve lives by researching, developing, and offering new therapies that address serious medical needs that currently lack effective solutions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
